One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients.
Journal Information
Full Title: Circ Cardiovasc Interv
Abbreviation: Circ Cardiovasc Interv
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Vascular Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosures Dr Kandzari reports institutional research/grant support from Biotronik, Boston Scientific, Medinol, Medtronic, OrbusNeich, and Teleflex and personal consulting honoraria from Biotronik, Cardiovascular Systems, Inc, and Medtronic. Dr Kirtane reports institutional funding to Columbia University or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, Cardiovascular Systems, Inc, Philips, and ReCor Medical; personal: Continuing Medical Education program honoraria and travel/meal reimbursements only. Dr Windecker reports research and educational grants to the institution from Abbott, Amgen, Bristol-Myers Squibb, Bayer, Boston Scientific, Biotronik, Cardinal Health, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Johnson & Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, and Sinomed. Dr Latib reports institutional research/grant support from Abbott, Boston Scientific, and Medtronic and personal consulting honoraria from Abbott and Medtronic. Dr Kedhi reports speaker honoraria from Medtronic, Abbott, Meril, and Daiichi Sankyo. Dr Mehran reports institutional research grants from Abbott Laboratories, AstraZeneca, Bayer, Beth Israel Deaconess, Bristol-Myers Squibb, Cardiovascular European Research Center, Chiesi, Concept Medical, CSL Behring, Daiichi-Sankyo, Inc, Medtronic, Novartis Pharmaceuticals, and OrbusNeich; consultant fees from Abbott Laboratories, Boston Scientific, Janssen Scientific Affairs, Medscape/WebMD, Medtelligence (Janssen Scientific Affairs), Roivant Sciences, Sanofi, and Siemens Medical Solutions; consultant fees paid to the institution from Abbott Laboratories and Bristol-Myers Squibb; advisory board, funding paid to the institution from Spectranetics/Philips/Volcano Corp; is a consultant (spouse) to Abiomed, The Medicines Company; equity <1% from Claret Medical and Elixir Medical; Data and Safety Monitoring Board Membership fees paid to the institution from Watermark Research Partners; consulting (no fee) from Idorsia Pharmaceuticals, Ltd and Regeneron Pharmaceuticals; is an associate editor for American College of Cardiology and American Medical Association. Dr Price reports institutional research/grant support from Daiichi Sankyo and personal consulting or speaking honoraria from Abbott Vascular, AstraZeneca, ACIST Medical, Boston Scientific, Chiesi USA, Medtronic, and W.L. Gore Medical. Dr Simon reports institutional research/grant support from Medtronic and personal educational honoraria from Medtronic. Dr Worthley reports research grants for Abbott and Biotronik. Dr Zaman reports consulting fees from Abbott, Boston Scientific, Medtronic, Meril, Sahajanand Medical Technologies, and Terumo. Dr Choi reports consulting fees from Medtronic. Dr Caputo reports consulting and speaking honoraria from Medtronic, Co, Merit Medical, Edwards Lifesciences, and Cardinal Health. Dr Potluri reports grant support, speaker or proctor, and honoraria from Terumo, Edwards, Medtronic, Boston Scientific, Cordis, Abbott, Philips, and Janssen. Dr Nazif reports institutional research/grant support from Medtronic and Boston Scientific and personal consulting fees or honoraria from Medtronic and Boston Scientific. M. Parke, Dr Lee, and Dr Lung are employees and shareholders of Medtronic. Dr Stone reports speaker or other honoraria from Cook, Terumo, QOOL Therapeutics, and Orchestra Biomed; is a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, and Matrizyme; and reports equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. The other authors report no conflicts."
"Sources of Funding This study was supported by Medtronic CardioVascular, Inc, Santa Rosa, CA."
"Registration:: URL: https://www.clinicaltrials.gov; Unique identifier NCT03647475."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025